Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly E Dooley

Showing results (1-10 of 170) with videos related to

Pageof 17
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?Kelly E Dooley
American Journal of Respiratory and Critical Care Medicine|July 12, 2018
High-Dose Rifampin: Shall We Be Bolder?Kelly E Dooley
Transactions of the American Clinical and Climatological Association|August 7, 2025
REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENTKelly E Dooley, Radojka Savic
The Lancet. HIV|May 25, 2023
Dolutegravir once daily with rifampicin for HIV and tuberculosisAnushka Naidoo, Kelly E Dooley
The Lancet. Respiratory Medicine|March 19, 2021
A leap forward in assessing host-directed therapies for tuberculosisElisa H Ignatius, Kelly E Dooley
Clinics in Chest Medicine|April 20, 2005
Treatment of latent tuberculosis infection: challenges and prospectsKelly E Dooley, Timothy R Sterling
Clinical Pharmacology and Therapeutics|August 24, 2018
State-of-the-Art Review of HIV-TB Coinfection in Special PopulationsEthel D Weld, Kelly E Dooley
Annual Review of Medicine|November 8, 2018
The Global Landscape of Tuberculosis TherapeuticsJeffrey A Tornheim, Kelly E Dooley
Expert Opinion on Drug Metabolism & Toxicology|July 25, 2019
Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosisChristine Sekaggya-Wiltshire, Kelly E Dooley
Current Opinion in HIV and AIDS|August 7, 2018
Challenges of TB and HIV co-treatment: updates and insightsJeffrey A Tornheim, Kelly E Dooley
Pageof 17

Showing results (1-10 of 170) with videos related to

Sort By:
Pageof 17
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?Kelly E Dooley
American Journal of Respiratory and Critical Care Medicine|July 12, 2018
High-Dose Rifampin: Shall We Be Bolder?Kelly E Dooley
Transactions of the American Clinical and Climatological Association|August 7, 2025
REVOLUTIONIZING TUBERCULOSIS REGIMEN DEVELOPMENTKelly E Dooley, Radojka Savic
The Lancet. HIV|May 25, 2023
Dolutegravir once daily with rifampicin for HIV and tuberculosisAnushka Naidoo, Kelly E Dooley
The Lancet. Respiratory Medicine|March 19, 2021
A leap forward in assessing host-directed therapies for tuberculosisElisa H Ignatius, Kelly E Dooley
Clinics in Chest Medicine|April 20, 2005
Treatment of latent tuberculosis infection: challenges and prospectsKelly E Dooley, Timothy R Sterling
Clinical Pharmacology and Therapeutics|August 24, 2018
State-of-the-Art Review of HIV-TB Coinfection in Special PopulationsEthel D Weld, Kelly E Dooley
Annual Review of Medicine|November 8, 2018
The Global Landscape of Tuberculosis TherapeuticsJeffrey A Tornheim, Kelly E Dooley
Expert Opinion on Drug Metabolism & Toxicology|July 25, 2019
Pharmacokinetic and pharmacodynamic considerations of rifamycin antibiotics for the treatment of tuberculosisChristine Sekaggya-Wiltshire, Kelly E Dooley
Current Opinion in HIV and AIDS|August 7, 2018
Challenges of TB and HIV co-treatment: updates and insightsJeffrey A Tornheim, Kelly E Dooley
Pageof 17